Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Incontinence07.01.06.011; 20.02.02.004; 17.05.01.0060.000052%Not Available
Increased appetite14.03.01.003; 08.01.09.0270.000112%Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Infertility female21.03.02.0170.000052%Not Available
Inguinal hernia07.16.02.0010.000035%Not Available
Injection site rash12.07.03.032; 08.02.03.032; 23.03.13.0100.000052%Not Available
Injury12.01.08.004--Not Available
Insomnia17.15.03.002; 19.02.01.002--
Interstitial lung disease22.01.02.003; 10.02.01.0330.000769%Not Available
Intestinal perforation07.04.06.0020.000227%Not Available
Intestinal stenosis07.13.01.0030.000052%Not Available
Intracranial pressure increased17.07.02.0020.000035%Not Available
Intraocular pressure increased13.07.04.002--Not Available
Intraventricular haemorrhage24.07.04.008; 17.08.01.0170.000035%Not Available
Intussusception07.13.01.0080.000105%Not Available
Iridocyclitis06.04.03.0010.000035%Not Available
Iron deficiency anaemia01.03.01.002; 14.13.02.0010.000070%Not Available
Irritability19.04.02.013; 08.01.03.0110.000559%
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.000210%Not Available
Joint effusion15.01.02.0050.000070%
Joint swelling15.01.02.0040.000350%Not Available
Kaposi's sarcoma16.33.02.001; 11.05.17.0010.000262%Not Available
Keratitis06.04.02.0020.000035%
Keratopathy06.06.03.0070.000052%Not Available
Kidney transplant rejection10.02.03.003; 20.01.02.009; 12.02.10.0040.000105%Not Available
Kyphosis15.10.04.0020.000070%
Lacrimation increased06.08.02.0040.000129%
Large intestinal ulcer07.04.06.0040.000087%
Large intestine perforation07.04.06.005; 12.02.03.0050.000210%
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.0030.000052%
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene